TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

TAVR vs. surgery among children and young adults with congenital heart disease

Though TAVR was once never considered a treatment option for younger patients, it is becoming more common as time goes on. 

Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings

Researchers aimed to shine light on this key topic, tracking data from nearly 200,000 patients. 

Left bundle branch block after TAVR hurts outcomes, even when no permanent pacemaker is required

Researchers tracked data from more than 2,000 TAVR patients, focusing on cardiovascular mortality and hospitalizations for heart failure. 

Transcatheter aortic valve replacement (TAVR) patients continue to benefit from an optimized pre- and post-procedural treatment strategy that utilizes the cusp overlap technique, according to new findings presented at EuroPCR 2022 in Paris.

Cusp overlap technique, optimized treatment strategy tied to significant improvements for TAVR patients

The research, presented at EuroPCR 2022 in Paris, represented an updated look at the Optimize PRO study, an ongoing analysis of patients treated with Medtronic’s self-expanding Evolut Pro and Pro+ TAVR systems.

New data on cardiac damage before and after AVR suggests earlier treatment may be beneficial

Patients with higher levels of extravalvular cardiac damage prior to TAVR or SAVR face a higher risk of dying within two years, according to new findings presented at EuroPCR 2022 in Paris.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TAVR vs. surgery: A new look at 1-year outcomes among moderate-risk patients with severe, symptomatic AS

All-cause mortality after one year was 4.6% for the TAVR group and 6.6% for the SAVR group

Thumbnail

TAVR safe and effective for patients with mixed aortic valve disease

MAVD patients did face a higher risk of requiring a permanent pacemaker, researchers noted, though the reason for this trend remains unclear. 

CT-FFR before TAVR improves detection of coronary artery disease, limits invasive imaging exams

CT-FFR, which recently got a boost from the 2021 AHA/ACC chest pain guidelines, could play a key role for clinicians hoping to screen TAVR patients for coronary heart disease. 

Displaying 281 - 288 of 419
Design by Adaptive Theme